Why Investors Are So Interested in Broadcom Stock
Broadcom’s dividend policy Previously in this series, we saw that Broadcom (AVGO) paid only 28% of its FCF (free cash flow) as dividends. The company expects acquisition, merger synergies, and…
NiSource (NI) stock had been trending upward around this time last year. But this year, it has yet to see such action.
According to a Business Wire report, on February 15, 2017, in a meeting of Time Warner’s (TWX) shareholders, 99% of share votes approved the AT&T (T) merger proposal.
On February 18, 2017, Bloomberg reported that Time Warner (TWX) and AT&T (T) had replied to a letter from 13 senators who criticized AT&T’s proposed acquisition of TWX.
On February 17, 2017, Time Warner (TWX) stock closed at $96.48. It has fallen a marginal 0.05% year-to-date (or YTD).
On February 13, 2017, Chemours (CC) announced an agreement with DuPont (DD) to resolve all indemnification obligations between them.
On February 14 and 15, 2017, Eastman Chemical (EMN) announced a price increase for acetic acid by $0.03 per lab in North America and Latin America.
On February 16, 2017, Huntsman received approval from the IRS to keep a 40.0% interest in Venator Materials.
On February 15, 2017, Air Products & Chemicals (APD) announced price hikes for its liquid and bulk industrial gas products in the North America.
On February 14, 2017, Celanese (CE) raised its selling price for LDPE (low-density polyethylene) resin polymers by $0.06 per pound, effective March 1, 2017.
On February 13, 2017, W.R. Grace (GRA) announced it will license its UNIPOL Polypropylene Process Technology to Dongguan Grand Resource.
Recently, Marathon Oil declared a dividend of $0.05 per share for 1Q17. The dividend will be payable on March 10, 2017, to stockholders of record at the close of business on February 15.
On February 16, 2017, Sanofi was trading at a forward PE multiple of ~13.9x, as compared to the industry average of 15.7x.
Sanofi Pasteur, Sanofi’s human vaccines business, reported a 3.7% sequential rise in revenues at constant exchange rates in 4Q16.
Sanofi’s (SNY) consumer healthcare franchise reported a 2.7% YoY growth in revenues at constant exchange rates.
Sanofi’s (SNY) established prescription products contributed nearly 28.9% of the company’s total 4Q16 revenues.
Sanofi has reorganized its diabetes and cardiovascular franchise, making it one of the largest revenue contributors to the pharmaceutical business.
Sanofi’s (SNY) 4Q16 revenues were mainly driven by Genzyme and Sanofi Pasteur.
Sanofi reported a sequential revenue growth of ~3.4% at constant exchange rates for 4Q16.
With DuPont stock continuing to rise, it’s trading 8.1% above its 100-day moving average of $72.10. The movement indicates the stock’s upward trend.